MyOme Expands Proactive Health Portfolio with Launch of Type 2 Diabetes Integrated Polygenic Risk Score (iPRS)™

MENLO PARK, Calif., Sept. 3, 2025 /PRNewswire/ -- MyOme, a leading clinical whole genome testing and polygenic risk modelling (PRS) company, today announced the launch of its Type 2 Diabetes (T2D) Integrated Polygenic Risk Score™ (iPRS). The new report, available as part of MyOme's Proactive Health products, empowers individuals and their healthcare providers with a more comprehensive understanding of inherited risk for developing T2D, one of the most prevalent chronic diseases worldwide.

According to the Centers for Disease Control and Prevention (CDC), more than 1 in 10 Americans—over 37 million people—have diabetes, with T2D accounting for 90–95% of cases.¹ An additional 96 million U.S. adults—over 1 in 3—have prediabetes, placing them at increased risk for developing T2D.² Diabetes is the eighth leading cause of death in the United States, contributing to approximately 100,000 deaths annually, and is recognized as a major public health concern by the CDC, NIH, and American Diabetes Association.³

The T2D iPRS combines insights from ~1.3 million genetic risk factors with clinical inputs from an individual's health history to deliver a more comprehensive and personalized assessment of T2D risk. By integrating both rare and common variants, MyOme's iPRS goes beyond traditional genetic testing to provide a fuller picture of risk that can inform earlier interventions and more tailored health decisions. By preventing or postponing disease onset, patients can enjoy longer, healthier lives, while health systems, employers, and insurers may see economic benefits.

"Our mission at MyOme is to enable people to take control of their health through their whole genome," said Dr. Akash Kumar, Chief Medical Officer at MyOme, "The addition of our T2D iPRS to our CAD iPRS strengthens our cardiometabolic portfolio, addressing two interrelated conditions that affect hundreds of millions globally. By combining insights into both cardiovascular and diabetes risk, we equip providers and patients with actionable tools to better guide prevention and long-term health."

The T2D iPRS joins MyOme's growing portfolio of Proactive Health offerings, which include:

• Single-Gene Screen Report: Identifies disease-causing variants in genes linked to a range of conditions including cancers, heart disease, and metabolic and inflammatory disorders.
• Medication Response Report: Detects genetic variants that influence how individuals metabolize commonly prescribed medications.
• Integrated Polygenic Risk Scores (iPRS):
  • Coronary Artery Disease (CAD) iPRS: Integrates millions of genetic markers with clinical factors to provide a personalized assessment of risk for heart attack and coronary events—enabling earlier interventions such as statin therapy, imaging, and lifestyle changes.
    
    
  • Breast Cancer iPRS: Combines genome-wide data with clinical inputs to stratify lifetime risk for breast cancer, supporting decisions around enhanced screening, preventive medication, and earlier detection strategies.
• Ongoing Access to Reports: MyOme participants receive updates as scientific knowledge evolves and new reports become available.

For more information about MyOme and its proactive health solutions, visit www.myome.com.

About MyOme
MyOme is a clinical whole genome analysis platform company helping families understand their risk for inherited diseases. As a leader in polygenic risk modeling, MyOme leverages the power of the whole genome for a lifetime of meaningful and actionable insights. Certified under the Clinical Laboratory Improvement Amendments (CLIA) and certified by the College of American Pathologists (CAP), MyOme is based in Menlo Park, California. For more information, please visit myome.com.

About Type 2 Diabetes

T2D is the most common form of diabetes, affecting more than 37 million people in the United States and over 460 million people worldwide.¹ T2D occurs when the body becomes resistant to insulin or when the pancreas cannot produce enough insulin, leading to elevated blood sugar levels. The condition is a major risk factor for heart disease, stroke, kidney disease, vision loss, and nerve damage.² In the U.S., diabetes is the eighth leading cause of death and costs more than $327 billion annually in direct medical expenses and lost productivity.³ Risk factors include family history, excess weight, physical inactivity, and poor diet. T2D often develops gradually, and many individuals may not notice symptoms for years. However, early identification of risk and preventive lifestyle changes can delay or even prevent onset of the disease.⁴

About MyOme's iPRS

MyOme's Integrated Polygenic Risk Score (iPRS) is a genetics-informed risk assessment that integrates information from a whole-genome analysis with family history and commonly collected clinical risk factors (e.g., BMI, blood glucose, lipids). The T2D iPRS has been validated across multiple ancestries, reflecting MyOme's cross-ancestry PRS (caPRS) approach that improves performance over several previously published models.⁵,⁶ Studies demonstrate that incorporating genetic risk with standard clinical factors provides better risk stratification compared to clinical risk scores alone, helping identify individuals at elevated risk for T2D who may benefit most from earlier prevention strategies.⁷

References

1. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2022.
2. Centers for Disease Control and Prevention. Prediabetes — Your Chance to Prevent Type 2 Diabetes. Accessed 2025.
3. American Diabetes Association. Statistics About Diabetes. Accessed 2025.
4. Mayo Clinic. Type 2 Diabetes — Symptoms and Causes. Accessed 2025.
5. Privé F, Aschard H, Blum MGB. Efficient implementation of penalized regression for genetic risk prediction. Genetics. 2019.
6. Duncan L et al. Analysis of polygenic risk score usage and performance in diverse human populations. Nat Commun. 2019.
7. Meigs JB et al. Genotype score in addition to common risk factors for prediction of Type 2 Diabetes. N Engl J Med. 2008.

SOURCE MyOme, Inc